沃替西汀:临床药代动力学与药物相互作用
沃替西汀是一种多模式活性新型抗抑郁药,用于治疗重度抑郁症,口服每日一次5-20 mg。其药代动力学呈线性且与剂量成比例,平均终末半衰期约66小时,稳态血浆浓度一般在给药2周内达到;平均绝对口服生物利用度为75%,未观察到食物影响。仅建议对CYP2D6慢代谢者调整剂量;除安非他酮和利福平外,其他评估药物的合用未对沃替西汀暴露或安全性产生有临床意义的影响。
要点
- 沃替西汀药代动力学线性,平均终末半衰期约66小时,稳态浓度一般2周内达到。
- 仅CYP2D6慢代谢者建议调整剂量;安非他酮和利福平合用需考虑剂量调整。
- 性别、年龄、种族、体型及肝肾功能未见临床相关暴露差异。
核心结论
- 沃替西汀在迄今研究的大多数人群中无需大幅调整剂量,但应根据患者个体情况考虑剂量调整。
研究设计与样本
- 本文为沃替西汀的临床药代动力学与药物相互作用综述,未报告系统检索范围。
主要发现
- 沃替西汀药代动力学呈线性且与剂量成比例,平均终末半衰期约66小时,稳态血浆浓度一般在给药2周内达到。
- 平均绝对口服生物利用度为75%,未观察到食物对药代动力学的影响。
- 沃替西汀经细胞色素P450酶代谢,随后经尿苷二磷酸葡萄糖醛酸转移酶代谢;主要代谢物无药理活性,次要活性代谢物预计不透过血脑屏障。
- 性别、年龄、种族、体型及肝肾功能未见沃替西汀暴露的临床相关差异。
- 仅建议对CYP2D6慢代谢者调整剂量;除安非他酮(强CYP2D6抑制剂)和利福平(广谱CYP诱导剂)外,其他评估药物的合用未对沃替西汀暴露或安全性产生有临床意义的影响。
关键数值与推荐
- 沃替西汀口服每日一次,剂量5-20 mg。
- 仅CYP2D6慢代谢者建议调整剂量。
- 安非他酮(强CYP2D6抑制剂)和利福平(广谱CYP诱导剂)合用可能影响沃替西汀暴露。
临床怎么用
- 大多数患者可使用沃替西汀而无需大幅调整剂量,但应根据个体情况考虑剂量调整。
- CYP2D6慢代谢者需调整剂量;合用安非他酮或利福平时应评估剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5- to 20-mg doses. The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-life of approximately 66 h and steady-state plasma concentrations generally achieved within 2 weeks of dosing. The mean absolute oral bioavailability of vortioxetine is 75%. No food effect on pharmacokinetics was observed. Vortioxetine is metabolized by cytochrome P450 enzymes and subsequently by uridine diphosphate glucuronosyltransferase. The major metabolite is pharmacologically inactive, and the minor pharmacologically active metabolite is not expected to cross the blood-brain barrier, making the parent compound primarily responsible for in-vivo activity. No clinically relevant differences were observed in vortioxetine exposure by sex, age, race, body size, and renal or hepatic function. Dose adjustment is only recommended for cytochrome P450 2D6 poor metabolizers based on polymorphism of the cytochrome P450 enzymes involved. Similarly, except for bupropion, a strong cytochrome P450 2D6 inhibitor, and rifampin, a broad cytochrome P450 inducer, co-administration of other drugs evaluated did not affect the vortioxetine exposure or safety profile in any clinically meaningful way. Pharmacodynamic studies demonstrated that vortioxetine achieved high levels of serotonin transporter occupancy in relevant brain areas, affected neurotransmitter levels in the cerebrospinal fluid, and modified abnormal resting state networks in the brain over the therapeutic dose range. Overall, vortioxetine can be administered in most populations studied to date without major dose adjustments; however, dose adjustments should be considered on a patient-by-patient basis.
引用
- Chen G, Højer AM, Areberg J, et al. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet. 2018. PMID: 29189941. doi:10.1007/s40262-017-0612-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。